United States - English - NLM (National Library of Medicine)

allergy laboratories, inc. - felis catus hair (unii: 1564hd0n96) (felis catus hair - unii:1564hd0n96) - felis catus hair 10000 [bau] in 1 ml - standardized cat hair extracts are indicated for the diagnosis of patients with a history of allergy to cats and for treatment of patients with cat allergy. diagnosis of allergic disease to cat hair is made through a combined medical history sufficiently complete to identify allergic symptoms to cat hair and identification of cat allergy by diagnostic skin testing. hyposensitization therapy is a treatment for patients exhibiting allergic reactions to cat. immunotherapy is intended for patients whose symptoms cannot be satisfactorily controlled by avoidance of the offending allergen or by the use of symptomatic medications. (5) there are no known absolute contraindications to hyposensitization therapy. see precautions section for pregnancy risks. a patient should not be treated with allergens unless a history of symptoms and a positive skin test reaction have been demonstrated. allergenic extracts should only be administered to patients that show symptoms of allergy or asthma. the physician must determine if t

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - clobetasol propionate, quantity: 0.05 % w/v - application - excipient ingredients: polyquaternium-10; ethanol; purified water; citric acid monohydrate; coco-betaine; sodium laureth sulfate; sodium citrate dihydrate - topical treatment of moderate to severe scalp psoriasis in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ethanol, quantity: 188 microlitre/ml; benzocaine, quantity: 75 mg/ml; clove bud oil, quantity: 190 microlitre/ml - application - excipient ingredients: propylene glycol - toothache medication. temporary relief from throbbing, persistent toothache due to a cavity.

Israel - English - Ministry of Health

merck sharp & dohme (israel-1996) ltd - tucatinib - film coated tablets - tucatinib 150 mg - tucatinib - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens.

Israel - English - Ministry of Health

merck sharp & dohme (israel-1996) ltd - tucatinib - film coated tablets - tucatinib 50 mg - tucatinib - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - tucatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium chloride; copovidone; potassium chloride; magnesium stearate; sodium bicarbonate; silicon dioxide; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - tukysa is indicated in combination with trastuzumab and capecitabine for treatment of patients with advanced unresectable or metastatic her2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-her2-based regimens in the metastatic setting. tukysa is indicated in combination with trastuzumab for the treatment of adult patients with ras wild-type her2 positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy. this indication was approved via the provisional approval pathway based on confirmed objective response rate (corr) in a single arm trial. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - tucatinib, quantity: 150 mg - tablet, film coated - excipient ingredients: silicon dioxide; sodium chloride; sodium bicarbonate; potassium chloride; magnesium stearate; crospovidone; copovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - tukysa is indicated in combination with trastuzumab and capecitabine for treatment of patients with advanced unresectable or metastatic her2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-her2-based regimens in the metastatic setting. tukysa is indicated in combination with trastuzumab for the treatment of adult patients with ras wild-type her2 positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy. this indication was approved via the provisional approval pathway based on confirmed objective response rate (corr) in a single arm trial. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

momentive performance materials inc. - trisiloxane ethoxylate - liquid - trisiloxane ethoxylate emulsifiers & surfactants-noni active 500.0 g/l - adjuvant - foliar nutrients additive | fungicide additive | growth regulator additive | insecticide additive | low volume application | ret - carrier - anti-evaporant | horticultural tree crops | spreading agent | vegetable - refer to label | vines - refer to label | wetting agent (use as directed) | adjuvant | apples | avocadoes | citrus | evaporant | herbicide application | improve penetrating properties | insecticide application | mangoes | olives | wetter

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - felis catus skin (unii: 5308ed00el) (felis catus skin - unii:5308ed00el) - felis catus skin 100 [bau] in 1 ml - this product is indicated for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to cats and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. there are no known absolute contraindications to immunotherapy. however, a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms and positive skin tests. in most cases, immunotherapy is not indicated for those allerg

Philippines - English - FDA (Food And Drug Administration)

isopropyl alcohol - topical solution classification: household remedy (hr) - 70% v/v dosage